PuSH - Publikationsserver des Helmholtz Zentrums München

Participation of pterins in the control of lymphocyte stimulation and lymphoblast proliferation.

Cancer Res. 43, 5356-5359 (1983)
DOI
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Biopterin accumulation had been demonstrated as the result of normal and, especially, of malignant hemopoietic cell proliferation . Among 13 major intermediates of pterin metabolism and two lumazines, xanthopterin (but not dihydroxyanthopterin) was found to inhibit cell proliferation (half-maximum inhibition at 1.8 x 10 -5 M) during concanavalin A-induced lymphocyte activation in pre-stimulated lymphocytes and in a lymphoid cel line grown in continuous culture (LS-2). LS-2 cells exposed to maximum inhibitor concentrations largely maintained the initial thymidine incorporation rate for about 40 hr but failed to enter logarithmic growth. Isoxanthopterin inhibition was found only in serum-free medium, since it is trapped by the α-acid glycoprotein present in the serum. The reduced biopterin derivatives, sepiapterin, dihydrobiopterin, and tetrahydrobiopterin, are costimulators during concanavalin A-induced lymphocyte activation. Their costimulatory effect follows an optimum curve and peaks at 1.5 to 3 x 10 -5 M. It is highest at the suboptimal and supraoptimal concanavalin A concentration. The D-erythro isomer dihydroneopterin was inactive. The results indicate that the anabolic-reduced biopterin derivatives are not simply lymphocytic products, but, in combination with the catabolites xanthopterin and isoxanthopterin, they also participate in the regulation of lymphocyte activation. Hence, they fulfill the criteria for lymphokines.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
ISSN (print) / ISBN 0008-5472
e-ISSN 1538-7445
Zeitschrift Cancer Research
Quellenangaben Band: 43, Heft: 11, Seiten: 5356-5359 Artikelnummer: , Supplement: ,
Verlag American Association for Cancer Research (AACR)
Verlagsort Philadelphia, Pa.
Begutachtungsstatus Peer reviewed
Institut(e) Institut für Toxikologie und Biochemie